Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

67.49
Delayed Data
As of Mar 23
 -0.34 / -0.50%
Today’s Change
65.38
Today|||52-Week Range
103.10
-5.75%
Year-to-Date
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valean...
Mar 22 / Zacks.com - Paid Partner Content
3 Reasons Why Gilead Sciences Will Buy Incyte -- and 1 Reason Why It Won't
Mar 15 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results
Mar 22 / Zacks.com - Paid Partner Content
Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
Mar 13 / Zacks.com - Paid Partner Content
Mylan Receives Tentative Approval from FDA for HIV Therapy
Mar 21 / Zacks.com - Paid Partner Content
3 Underdog Stocks We're Watching Closely
Mar 13 / MotleyFool.com - Paid Partner Content
Biotech Bull Making a Comeback
Mar 21 / Zacks.com - Paid Partner Content
3 Healthcare Stocks That Are Looking Cheap
Mar 12 / MotleyFool.com - Paid Partner Content
North Tide Capital, Llc Buys Impax Laboratories, Allergan PLC, Accuray, Sells Communi...
Mar 20 / GuruFocus News - Paid Partner Content
Which Biotech Is the Best Dividend Stock?
Mar 11 / MotleyFool.com - Paid Partner Content
Why Biotech Stock Gilead (GILD) Could Be a Value Trap
Mar 20 / Zacks.com - Paid Partner Content
AbbVie Stock Upgraded: What You Need to Know
Mar 10 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data
Mar 16 / Zacks.com - Paid Partner Content
How Incyte Stock Became a Bull Market Star for Biotech Investors
Mar 10 / Zacks.com - Paid Partner Content
Forget Gilead, Buy These Small-Cap Biotech Stocks Instead
Mar 15 / Zacks.com - Paid Partner Content